Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Yoshiyuki Yabe"'
Autor:
Masataka Oitate, Toshinori Agatsuma, Koji Morita, Takeshi Masuda, Mayumi Goto, Takashi Nakada, Yuki Abe, Michiko Kitamura, Hideo Yukinaga, Junko Yamaguchi, Takuma Iguchi, Tomoko Terauchi, Yusuke Ogitani, Koichi Goto, Yoshiyuki Yabe
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 26:5069-5072
To establish a novel and widely applicable payload-linker technology for antibody-drug conjugates (ADCs), we have focused our research on applying exatecan mesylate (DX-8951f), a potent topoisomerase I inhibitor, which exhibits extensive antitumor ac
Publikováno v:
Drug Metabolism and Disposition. 39:1808-1814
To explore the determinants of hepatic uptake, 16 compounds were investigated with different physicochemical and disposition characteristics, including five statins, three sartans, saquinavir, ritonavir, erythromycin, clarithromycin, nateglinide, rep
Autor:
Takashi Izumi, Noriko Okudaira, Yoshiyuki Yabe, Takanori Aoki, Nobuyuki Murayama, Atsushi Kurihara, Noriko Masubuchi, Masataka Oitate, Tsuyoshi Karibe, Takashi Ito
Publikováno v:
Drug Metabolism and Pharmacokinetics. 26:423-430
Interspecies allometric scaling is a useful tool for calculating human pharmacokinetic (PK) parameters from data in animals. In this study, in order to determine the scaling exponent in a simple allometric equation that can predict human clearance (C
Autor:
Kyosuke Tanaka, Yoshiyuki Yabe, Atsushi Yamasaki, Koichi Nakamura, Nobuo Machinaga, Yasushi Yoshigae, Gary W. Ashley, Daniel V. Santi, Ralph Reid
Publikováno v:
Translational Vision Science & Technology
Purpose The short half lives of small molecules in the vitreous requires frequent repeated intravitreal injections that are impractical for treatment of chronic eye diseases. We sought to develop a method for increasing the intravitreal half-life of
Autor:
Rira Watanabe, Mayumi Kanda, Wakaba Matsumoto, Yoshiyuki Yabe, Hideo Kobayashi, Masayuki Takahashi, Norio Suzuki, Yuki Kawabata, Masaru Iwasaki
Publikováno v:
Drug Metabolism and Pharmacokinetics. 33:S41
Publikováno v:
Biological and Pharmaceutical Bulletin. 29:1926-1930
To investigate the effect of functional groups in bovine serum albumin (BSA) on its tissue distribution characteristics, tyrosine (Tyr) or tryptophan (Trp) residues of BSA were chemically modified by tetranitromethane (TNM) and 2-hydroxy-5-nitrobenzy
Autor:
Yoshinobu Takakura, Yukari Umeyama, Yuki Takahashi, Kenji Hyoudou, Hitomi Kumai, Yuki Kobayashi, Emi Ishida, Frantisek Staud, Yoshiyuki Yabe, Mitsuru Hashida, Ayumi Tamada, Makiya Nishikawa, Fumiyoshi Yamashita
Publikováno v:
ResearcherID
Bovine liver catalase derivatives possessing diverse tissue distribution properties were synthesized, and their effects on hepatic metastasis of colon carcinoma cells were examined in mice. An intraportal injection of 1 × 105 colon 26 cells resulted
Publikováno v:
Free Radical Research. 30:265-274
To explore the possibility of using catalase for the treatment of reactive oxygen species (ROS)-mediated injuries, the pharmacokinetics of bovine liver catalase (CAT) labeled with 111In was investigated in mice. At a dose of 0.1 mg/kg, more than 70%
Autor:
Kenzo Sawai, Yoshikazu Oka, Akira Takagi, Mitsuru Hashida, Yoshinobu Takakura, Yoshiyuki Yabe
Publikováno v:
Pharmaceutical Research. 14:86-90
Purpose. To clarify the mechanism of the renal clearance of recombinant human interleukin-11 (rhIL-11), we investigated the renal disposition characteristics of rhIL-11 in the perfused rat kidney.
Autor:
Yoshiyuki Yabe, Tsuyoshi Nakamura, Futoshi Nara, Yumi Kawase, Masayoshi Asano, Takaichi Shimozato, Kazuhiko Tamaki, Ryotaku Inoue, Daisuke Nakai, Wataru Tomisato, Yoko Urasaki-Kaneno, Hiromi Doi-Komuro, Takahide Nishi, Hiroshi Yuita, Keiko Oguchi-Oshima, Yumiko Mizuno, Miyuki Nagasaki, Emi Kamiyama, Yukiko Sekiguchi, Reina Kaneko, Takashi Kagari
Publikováno v:
European journal of medicinal chemistry. 51
Modulators of sphingosine phosphate receptor-1 (S1P(1)) have recently been focused as a suppressant of autoimmunity. We have discovered a 4-ethylthiophene-based S1P(1) agonist 1-({4-Ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)